Preprint
via Europe PMC
Polycomb Marked Promoter Methylation Gains in Aging and Cancer are Independent of Replication
Thursby S, Patel N, Jin Z, Blum J, Bisht S, Tao Y, Bhandari Y, Petkovich D, Ro H, Yang L, Wang T, Pisanic TR, Baylin SB, Easwaran H.
· 2026
Abstract
DNA methylation alterations are hallmark features of aging and cancer, occurring early during tumor initiation. Yet how these changes evolve during early tumorigenesis, and whether oncogenic signaling actively drives them, remains poorly understood due to limitations in resolving this at the longitudinal and clonal level. Here we developed a genome-wide DNA methylation profiling method for low DNA amounts and applied it to single stem cell-derived clones from a BRAF V600E -inducible mouse colon organoid model, tracking nucleotide-level methylation heterogeneity over time. BRAF V600E induction produced stepwise methylation divergence consistent with progressive clonal takeover, in contrast to gradual epigenetic drift in uninduced controls. Strikingly, while the specific CpG sites altered differed between BRAF V600E and control lineages, they converged on the same genomic elements. Particularly, Polycomb-marked promoter CpG-island methylation gains were not induced or accelerated by BRAF V600E , challenging models in which oncogenic signaling or cell proliferation actively instructs de novo methylation of Polycomb-targeted promoters. Instead, these gains tracked with “biological aging” independent of replication, which was validated across independent aging, cancer, and cell-line datasets. BRAF V600E -induced clones additionally showed progressive loss of intestinal lineage-specification transcription factor programs, consistent with selection for cells adapted to oncogenic stress. Together, these findings show that epigenetic trajectories during early tumor development, are rooted in baseline, age-dependent drivers of epigenetic alterations, and that oncogenic signaling acts primarily by selecting and expanding clones bearing pre-existing, age-associated epigenetic drift rather than instructing new methylation. Our findings have implications for how promoter methylation is interpreted as a cancer biomarker and for identifying upstream aging-associated processes as targets for early intervention.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.64898/2026.10.30.763235
- Canonical
- link ↗
- Fetched
- 2026-11-06 MST
Cite this
APA
S, T., N, P., Z, J., J, B., S, B., Y, T., Y, B., D, P., H, R., L, Y., T, W., TR, P., SB, B., & H., E. (2026). Polycomb Marked Promoter Methylation Gains in Aging and Cancer are Independent of Replication. https://doi.org/10.64898/2026.10.30.763235
Vancouver
S T, N P, Z J, J B, S B, Y T, et al. Polycomb Marked Promoter Methylation Gains in Aging and Cancer are Independent of Replication. 2026. doi:10.64898/2026.10.30.763235.
BibTeX
@unpublished{thursby2026Polyco,
title = {Polycomb Marked Promoter Methylation Gains in Aging and Cancer are Independent of Replication},
author = {Thursby S and Patel N and Jin Z and Blum J and Bisht S and Tao Y and Bhandari Y and Petkovich D and Ro H and Yang L and Wang T and Pisanic TR and Baylin SB and Easwaran H.},
year = {2026},
doi = {10.64898/2026.10.30.763235},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Brain Behavior & Immunity - Health 2026
Open access · CC-BY
The role of health behaviors in links between stress and epigenetic aging
Experimental Biology and Medicine 2020
Preprint · OA
Current perspectives on the cellular and molecular features of epigenetic ageing
Epigenomes 2026
Open access · OA
Age-Related Epigenetic Drift Shapes Coordinated microRNA Promoter Methylation and Expression in Prostate Cancer.
bioRxiv (Cold Spring Harbor Laboratory) 2025
Preprint · CC-BY
Epigenetic age prediction using N6-methyladenine in the bumblebee Bombus terrestris
Psychology and Aging 2021
Open access · OA
An older subjective age is related to accelerated epigenetic aging.
2026
Preprint